Vimarsana
Biggest News Aggregation in the World

Page 7 - Acticor Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acticor Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acticor Biotech Today - Breaking & Trending Today

Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA - Vimarsana News

Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA

Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular

Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023 - Vimarsana News

Acticor Biotech Announces Its Financial Agenda for The 1st Half of 2023

Regulatory News: Acticor Biotech (Euronext Growth Paris ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company, a spin-off of INSERM, developing an innovative drug for

World's first clinical trial to test new drug glenzocimab for heart attacks - Vimarsana News

World's first clinical trial to test new drug glenzocimab for heart attacks

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth ...

Acticor Biotech starts trial for heart attack drug Glenzocimab - Vimarsana News

Acticor Biotech starts trial for heart attack drug Glenzocimab

Acticor Biotech's glenzocimab, a potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K.

First clinical trial to test novel heart attack drug - Vimarsana News

First clinical trial to test novel heart attack drug

The first clinical trial for new heart attack drug glenzocimab, will evaluate its ability to reduce heart damage following a heart attack.